Member Info for Misterh

Share consolidation 1 for 10. Supposed to increase liquidity, but spread as wide as ever!

I think it's fair to say that the take up of the above was pretty impressive, closing early with 1.2M raised. I presume therefore the total raised was 3.35M with 8.375M new shares issued which will represent 18.5% of the enlarged issued share capital.
This is a fairly significant dilution at an eye-watering discount, something that is never welcome news to retail investors.
However, the balance sheet is considerably strengthened and some of the expensive debt can be paid down [just look at the finance costs on the cash flow statement], leaving plenty of cash to invest in marketing. If the company has truly reached an 'inflection point' as management claim, exciting times could lie ahead.

An interesting point. It does however seem inconceivable that the VOC digital fingerprint could vary to any significant degree from one strain to another. Surely it would not be able to tell for example what strain of Salmonella is present in the hen house. I'd be happy to be proven wrong though as almost anything seems possible these days!
I am inclined to think that the Kromek technology will ultimately be superior in this regard.

That's great thanks mike33.
I agree that the commercial opportunities for such a device are very exciting.
I was also thinking about intensive farming situations and the early detection, for example, of new and existing strains of infectious bronchitis virus [a Coronavirus in poultry that's plagued the industry for years]
Perhaps Dr Basu wasn't exaggerating when he referred to it as 'disruptive technology'

Am I right in thinking that the detectors made by rival companies such as Smiths have to be loaded with agent specific biosensors [e.g. one biosensor disc for SARS-COV-2 and so on], whereas the Kromek device is able to read the full genome of any pathogen that happens to be present? If therefore say a novel Corona virus or Influenza type A virus were to appear on the scene, does that mean it would only be precisely identified by the Kromek device? If so, that would make it vastly superior and possibly unique in the market.
Is anyone able to shed more light on this?

There's a lot to like in this latest RNS. The key financials are more than respectable and the comments on current trading and outlook encouraging. Of most interest is 'giving consideration to growing by acquisition'. How would they finance such an acquisition? Raising the cash through debt or equity would come at a high cost. Perhaps a synergistic all-share merger with a similar sized company would make sense. Management is nothing if not ambitious and they are operating in the right sector at the right time.
I think this company has a great future and I remain a buyer.

Too much excitement for one day. We can now all return to our slumbers before the next RNS around 2nd December.

Just published: ' Chariot Oil fundraise to accelerate Moroccan gas project'
May give flagging SP a much needed fillip.

Despite more positive RNS's in the last year than you can shake a stick at, the SP is now down year on year. It's difficult to get your head around the reason for such poor sentiment.
I still feel very optimistic about the long term prospects for this company and am more than happy to average down at this price.

After the underwhelming update and the miserable dividend declaration, decided to sell after holding for three years with a small loss [excluding dividends]. Looks like Bearbull in the IC is about to do the same. 'Instinct says R and Q's story will be better than reality and a share holding that has done very little since it was acquired should be dumped'
Although the column has a lot of followers, I don't think it will have any influence on the SP.
Best of luck to remaining holders.

Can't see this raising more than a couple of beans, although management will have factored this into the equation knowing the share price would likely tank after the announcement. There should be plenty of opportunities however to avoid dilution in the coming months if you still believe in the Chariot story [increasingly difficult I know]. With a lack of any significant positive news flow and the energy sector falling in and out of favour, I would be very surprised if you were unable to buy at a very significant discount to the current share price at some point in the coming months. How low you venture to go is the only difficult bit.

RNS just in: 1 for 10 consolidation.
Of more interest is talk of dividends and share buybacks. About time too.

At 120p on the current offer price, this looks like seriously good long term value. This equates to a market cap of just GBP69M.
Pro forma net cash following completion should be around GBP32.8M.
The group will continue to own 8% of QCL holdings [ if they exercise their options] which will enjoy the financial muscle Northleaf and is near certain to prosper and grow exponentially.
Not to forget the retained fast growing Australian and Nordic businesses brought in a top line of GBP22.9M last year. I would hope for a decent operating profit this year. Finance costs should be eliminated as all borrowings will have been paid down.
Of interest is that they state that options for the Skymesh business include disposal as well as a possible IPO.
Clearly they want to focus in particular on the Nordic business where there is plenty of scope for growth. Not to forget that Norway in particular is an extremely business friendly jurisdiction.
It's hard to see how you can go seriously wrong at this price, so very happy to add to my holdings this morning.

Just published 'Profit from big data analytics'

Maintains 100p price target based on 10 x forecast cash profit in 2022 of USD3.5M

Should catch the attention of quite a few readers tomorrow.

I think there is a very good chance that the shares will respond positively when the above is announced following the publication of the annual financial report at the end of April. The house broker is expecting 2p which would be very generous for a fast growing technology company and would likely attract new investors. Bear this in mind when timing entry.

I was very impressed with the news about the revolutionary TB test. To identify the strain involved and the antibiotic resistance profile within a couple of hours is truly innovative and addresses a major global health issue.
People prattle on about ESG and ethical investing but if you are really serious about such things, then look no further than BVC for a core holding.
I have a strong feeling it will be very profitable to boot.

It may be worth giving A.J. Bell a call. They were very efficient when I transferred some paper share certificates [albeit UK stocks] to my online dealing account last year. They also seemed relatively quick in processing the transfer of my CNEL holding, which were available for dealing quite early on. One downside though is the minimum deal size of £10,000 should I wish to add to my holding.

I think that the takeover of GenMark by Roche for a substantial premium is of significance. It would appear that they specifically wanted exposure to the diagnostic panels that rapidly detect multiple respiratory disease causing pathogens.
Given that this is very similar to what BATM have developed, I wonder what the Bio-Medical Division alone is now worth.
I am starting to feel very comfortable holding shares in this dynamic and innovative company.

I got approximately 6% of the additional shares I applied for which seems in keeping with the high level of oversubscription.

XD on 4.3.21, so plenty of time to buy in to qualify.